The short answer
Kava may add to eszopiclone-related drowsiness and next-day impairment. Review co-use before adding it, especially when the supplement is being used as another sleep aid.
What this answer covers
Piper methysticum oral beverages and extracts; plant part and preparation matter.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- eszopiclone
Eszopiclone’s impairment warning matters
LUNESTA labeling warns of additive CNS depression and next-day impairment, and does not recommend other sedative-hypnotics at bedtime or during the night. This is a co-use precaution, not a measured adverse-event rate for this supplement.
What is known about this product
Supplement-specific evidence describes drowsiness or cautions about sedative co-use. The inspected sources do not establish the risk or benefit of this exact combination.
Negative findings have a limited scope
The label reports no clinically relevant interaction after single doses with lorazepam, while warning that this does not establish absence of effects during chronic use. Other combinations did impair performance. These findings do not prove either safety or harm for an untested supplement combination.
Plan co-use with the prescriber
Discuss the exact product and other sleep medicines before adding it. A short spacing interval has not been shown to prevent additive impairment. Do not drive while impaired. If sleepwalking, sleep-driving or other activities while not fully awake occur, stop eszopiclone and contact the prescriber promptly, as its label instructs.
Evidence and practical considerations
Side effects & toxicity
Conditional additive-sedation and co-use review precaution from exact medication labeling and supplement evidence. No measured pair incidence or protective timing interval; no claim of a universal botanical contraindication.
- Exact scope
- Piper methysticum oral beverages and extracts; plant part and preparation matter. with Eszopiclone461016 IN; oral LUNESTA tablets, distinct from racemic zopiclone.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed eszopiclone
CYP3A4/2E1 metabolism; ketoconazole increased exposure2.2fold. Rifampicin induction evidence measured racemic zopiclone, extrapolated by label. Additive CNS depression and boxed complex sleep behavior warning.
How this applies: Exact eszopiclone RxCUI 461016 IN, with stated salt/formulation/route bridge.
Other-drug results do not establish exact botanical effects; single-dose lorazepam/paroxetine nulls do not predict complete absence of chronic pharmacodynamic effects.
Source 2: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Kava should not be used with other sedating substances. Various kava products have been linked to rare liver injury, sometimes serious or fatal.
How this applies: Original source interpreted for eszopiclone only within the stated preparation and endpoint limits.
Not a direct eszopiclone combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 participants with anxiety and insomnia.
Neither botanical improved its primary anxiety/insomnia outcome over placebo.
How this applies: Original source interpreted for eszopiclone only within the stated preparation and endpoint limits.
Four-week kava/valerian insomnia/anxiety efficacy trial; failure to show benefit is not proof of absent sedation. No eszopiclone combination.
Research assessment: · Open full citations ↗
Timing & monitoring
Conditional additive-sedation and co-use review precaution from exact medication labeling and supplement evidence. No measured pair incidence or protective timing interval; no claim of a universal botanical contraindication.
- Exact scope
- Piper methysticum oral beverages and extracts; plant part and preparation matter. with Eszopiclone461016 IN; oral LUNESTA tablets, distinct from racemic zopiclone.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed eszopiclone
CYP3A4/2E1 metabolism; ketoconazole increased exposure2.2fold. Rifampicin induction evidence measured racemic zopiclone, extrapolated by label. Additive CNS depression and boxed complex sleep behavior warning.
How this applies: Exact eszopiclone RxCUI 461016 IN, with stated salt/formulation/route bridge.
Other-drug results do not establish exact botanical effects; single-dose lorazepam/paroxetine nulls do not predict complete absence of chronic pharmacodynamic effects.
Source 2: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Kava should not be used with other sedating substances. Various kava products have been linked to rare liver injury, sometimes serious or fatal.
How this applies: Original source interpreted for eszopiclone only within the stated preparation and endpoint limits.
Not a direct eszopiclone combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 participants with anxiety and insomnia.
Neither botanical improved its primary anxiety/insomnia outcome over placebo.
How this applies: Original source interpreted for eszopiclone only within the stated preparation and endpoint limits.
Four-week kava/valerian insomnia/anxiety efficacy trial; failure to show benefit is not proof of absent sedation. No eszopiclone combination.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Prepared exact eszopiclone article with formulation-specific evidence and uncertainty. |
Article revision: 4e0e1b277715633b
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.